Popular Trials
Monoclonal Antibodies
GCS-100 for Diabetic Kidney Disease
A phase 2b, placebo-controlled, randomized, double-blind, multi-center study of GCS-100 in patients with chronic kidney disease caused by diabetes. The study will enroll approximately 375 patients at multiple centers located in the United States. Study duration is 6 months. Patients will be randomly assigned 1:1:1:1 to treatment with placebo (0.9% Sodium Chloride Injection, USP), 1 mg, 3 mg, or 9 mg GCS-100. All doses of study drug will be administered via intravenous (IV) push injection once weekly for 2 months (8 weeks), then every other week for an additional 4 months (16 weeks).
Vitamin D Analog
Paricalcitol (Zemplar) for Type 2 Diabetes
The purpose of this research study is to study the effects of paricalcitol on endothelial function and inflammation, cardiovascular risk factors which are associated with patient populations that have Type 2 diabetes and Stage 3 and 4 Chronic Kidney Disease (CKD). Hypothesis 1: The state of CKD is associated with oxidative stress and inflammation and impaired post ischemic endothelium dependent flow mediated vasodilation which may contribute to atherogenesis. Hypothesis 2: The administration of paracalcitol to patients with CKD will suppress oxidative stress and inflammation and improve endothelial function and thus contribute to an anti-atherogenic action.
Stem Cell Transplant
Bone Marrow/Kidney Transplant for Blood Disorders & Chronic Kidney Disease
This trial is for a combined bone marrow and kidney transplant from a partially matched related donor to treat a blood disorder and kidney disease. The expectation is to have 10 people participate.
Vitamin D Supplement
Cholecalciferol for Chronic Kidney Disease
To determine whether or not chronic kidney disease (CKD), stages III-V and ESRD , is associated with altered vitamin D metabolism related to fibroblast growth factor-23 (FGF-23) stimulation of Cyp24 and whether they have resistance to elevations of 25 Hydroxyvitamin D (25(OH)D3) after cholecalciferol supplementation. To determine if such resistance is related to enhanced catabolism of (25(OH)related to elevated levels of FGF-23.
Electronic Pillbox Monitoring System for Medication Adherence
The objective of this pilot study is to explore barriers to medication adherence among HPHC members with CKD, particularly those not yet on dialysis, and to assess the feasibility and acceptability of a wireless, internet-based MedMinder system intervention among HPHC enrollees with CKD and their care partners. The investigators hypothesize that the intervention will improve medication use and adherence among patient members with CKD on complex medication treatment, and improve informal caregivers' ability to provide support for improved medication use among patient members.
Popular Filters
Trials for CKD Patients
Behavioural Intervention
ImPart for Chronic Kidney Disease
"This trial aims to test a new method called Multiphase Optimization Strategy (MOST) to help improve the decision-making skills of people with stage 4 chronic kidney disease and their caregivers. The study will
Stem Cell Therapy
Stem Cell Infusion for Kidney Transplant Tolerance
This trial will study whether patients with a kidney transplant from a HLA-identical living donor can stop taking immunosuppressive drugs without damaging the transplanted kidney, by receiving hematopoietic stem cells from the same donor.
Behavioural Intervention
Computerized Decision Support for Chronic Kidney Disease in Type 2 Diabetes
This trial will assess the impact of an EPIC Best Practice Advisory (BPA; alert-based CDS tool) on guideline-directed assessment for CKD using UACR in patients with T2DM who have not had a UACR in the past year.
Diuretic
Diuretics for Early Chronic Kidney Disease
This trial is testing whether medications that help remove extra fluid from the body can improve heart health in Veterans with early-stage kidney disease and high blood pressure. By reducing fluid volume, these medications may lower blood pressure and decrease heart strain. These medications have been used to manage extra fluid buildup and control blood pressure in various conditions, including heart failure and high blood pressure, for many years.
Opioid Analgesic
Oxycodone for Chronic Kidney Disease
To measure oxycodone's intradialytic mass transfer rate coefficient and oxycodone's removal rate using an ODE/PDE hemodialysis model. To implement a rational clinical strategy for estimating a patient's post-hemodialysis oxycodone restoration dose using results from an ODE/PDE model of hemodialysis.
Trials for Kidney Failure Patients
Behavioural Intervention
ImPart for Chronic Kidney Disease
"This trial aims to test a new method called Multiphase Optimization Strategy (MOST) to help improve the decision-making skills of people with stage 4 chronic kidney disease and their caregivers. The study will
Stem Cell Therapy
Stem Cell Infusion for Kidney Transplant Tolerance
This trial will study whether patients with a kidney transplant from a HLA-identical living donor can stop taking immunosuppressive drugs without damaging the transplanted kidney, by receiving hematopoietic stem cells from the same donor.
Behavioural Intervention
Computerized Decision Support for Chronic Kidney Disease in Type 2 Diabetes
This trial will assess the impact of an EPIC Best Practice Advisory (BPA; alert-based CDS tool) on guideline-directed assessment for CKD using UACR in patients with T2DM who have not had a UACR in the past year.
Diuretic
Diuretics for Early Chronic Kidney Disease
This trial is testing whether medications that help remove extra fluid from the body can improve heart health in Veterans with early-stage kidney disease and high blood pressure. By reducing fluid volume, these medications may lower blood pressure and decrease heart strain. These medications have been used to manage extra fluid buildup and control blood pressure in various conditions, including heart failure and high blood pressure, for many years.
Phase 3 Trials
Hormone Therapy
Melatonin for Sleep Disorders
The study will evaluate the safety and efficacy of melatonin supplementation in CKD and ESRD patients with sleep disorders to reduce sleep latency times, the number of apnea/hypopneic episodes, and prolong duration in rapid eye movement (REM) sleep in CKD and ESRD patients with sleep disordered breathing.
Trials With No Placebo
Hormone Therapy
Hormone Monitoring for Hyperparathyroidism
"This trial aims to see if using intraoperative parathyroid hormone (IOPTH) criteria during surgery for secondary and tertiary hyperparathyroidism is feasible. Patients will be randomly assigned to have surgery
Behavioural Intervention
ImPart for Chronic Kidney Disease
"This trial aims to test a new method called Multiphase Optimization Strategy (MOST) to help improve the decision-making skills of people with stage 4 chronic kidney disease and their caregivers. The study will
Stem Cell Therapy
Stem Cell Infusion for Kidney Transplant Tolerance
This trial will study whether patients with a kidney transplant from a HLA-identical living donor can stop taking immunosuppressive drugs without damaging the transplanted kidney, by receiving hematopoietic stem cells from the same donor.
Behavioural Intervention
Computerized Decision Support for Chronic Kidney Disease in Type 2 Diabetes
This trial will assess the impact of an EPIC Best Practice Advisory (BPA; alert-based CDS tool) on guideline-directed assessment for CKD using UACR in patients with T2DM who have not had a UACR in the past year.
Diuretic
Diuretics for Early Chronic Kidney Disease
This trial is testing whether medications that help remove extra fluid from the body can improve heart health in Veterans with early-stage kidney disease and high blood pressure. By reducing fluid volume, these medications may lower blood pressure and decrease heart strain. These medications have been used to manage extra fluid buildup and control blood pressure in various conditions, including heart failure and high blood pressure, for many years.
View More Related Trials
Frequently Asked Questions
Introduction to chronic kidney disease
What are the top hospitals conducting chronic kidney disease research?
When it comes to advancing the understanding and treatment of chronic kidney disease, several hospitals are making notable contributions through their active clinical trials. In San Antonio, the Clinical Advancement Center, PLLC is at the forefront with four ongoing trials dedicated to chronic kidney disease. This center is committed to exploring new avenues in research for this debilitating condition. Similarly, Vanderbilt University Medical Center in Nashville has three active trials focused on chronic kidney disease. Known for its esteemed reputation in medical research and education, Vanderbilt is playing a crucial role in uncovering innovative approaches to managing this complex disease.
In Waterbury, Chase Medical Research LLC also joins the list with three ongoing clinical trials centered around chronic kidney disease. This facility's dedication to investigating potential treatments speaks volumes about their commitment towards improving outcomes for patients living with this condition.
Meanwhile, Cleveland Clinic located in Cleveland stands out as a leading institution driving progress against chronic kidney disease through three active clinical trials aimed at enhancing our understanding of this ailment and finding effective solutions. Lastly but not least significant is Novo Nordisk Investigational Site situated in San Dimas where they too actively participate by conducting three clinical examinations concentrated on studying severe cases relating to Chronic Kidney Disease (CKD).
These pioneering hospitals across different locations are united by their shared mission: tackling one of humanity’s most challenging health issues - chronic kidney disease; By continually pushing boundaries through rigorous research efforts; these institutions offer hope and promise for individuals affected by CKD worldwide
Which are the best cities for chronic kidney disease clinical trials?
When it comes to chronic kidney disease clinical trials, several cities have emerged as leaders in research and development. Houston, Texas leads the way with 22 active trials investigating treatments like Cohort 2, Doxercalciferol (GZ427397), and Semaglutide. Chicago, Illinois closely follows with 19 ongoing studies focusing on innovations such as Finerenone (BAY94-8862) and various arms of Cohort 2. San Antonio, Texas also shows promising progress with 18 active trials exploring treatments like Semaglutide and CIN-107. Additionally, Los Angeles, California and Kansas City, Missouri each contribute significantly to the field with their own set of active trials examining a range of potential therapies for chronic kidney disease patients. These cities serve as important hubs for cutting-edge research that holds promise for improving care outcomes in this challenging condition.
Which are the top treatments for chronic kidney disease being explored in clinical trials?
Clinical trials are paving the way for groundbreaking treatments in chronic kidney disease (CKD). Among the top contenders is tolvaptan, a medication being explored in four active clinical trials. Another promising option is bardoxolone methyl, currently undergoing evaluation in three ongoing CKD studies. Additionally, sparsentan has generated significant interest with its potential therapeutic benefits and participation in two active trials. These innovative treatments offer hope for patients battling this debilitating condition and signify progress towards improving outcomes and quality of life for individuals affected by CKD.
What are the most recent clinical trials for chronic kidney disease?
Promising advancements in the field of chronic kidney disease (CKD) are emerging through recent clinical trials. One noteworthy study explores an intervention group, undergoing both Phase 1 and Phase 2 trials, aiming to improve CKD management. Another trial focuses on a dedicated Chronic Kidney Disease Group for patients, providing potential insights into effective treatment approaches. Additionally, there is ongoing investigation into the benefits of consuming alkalizing fruit and vegetables as part of managing CKD symptoms. Furthermore, a Phase 2 trial examines LY3437943's efficacy in addressing this condition while Renal Autologous Cell Therapy (REACT), currently undergoing Phase 1 testing, offers hope for innovative therapeutic options moving forward. These studies foster optimism within the CKD community by expanding our understanding and paving the way towards improved care strategies.
What chronic kidney disease clinical trials were recently completed?
Several recent clinical trials have concluded, focusing on advancing treatments for chronic kidney disease (CKD). One notable achievement was the completion of a trial investigating the efficacy of Uproleselan, sponsored by Washington University School of Medicine in October 2021. Additionally, a trial examining mRNA-1273 therapy, led by the National Cancer Institute and completed in September 2021, showcased promising results for CKD patients. These significant milestones highlight ongoing efforts to improve treatment options and outcomes for individuals living with this challenging condition.